author-photo

Panayiotis Panayiotidis

National and Kapodistrian University of Athens

224

Papers

4555

Citations

Citation Trend

Filter By

Papers (154) Sort By

Journal Conference Others

Bone marrow ribonucleotide reductase mRNA levels and methylation status as prognostic factors in patients with myelodysplastic syndrome treated with 5-Azacytidine.

2021 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (0)
Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI.

2021 Leukemia
Show All
- Source
- Cite
- Save
Citations (2)
Richter's transformation as leptomeningeal infiltration in a chronic lymphocytic leukemia patient receiving venetoclax. Could blood‐brain barrier be a disease “sanctuary” during venetoclax treatment?

2021 Clinical Case Reports
Show All
- Source
- Cite
- Save
Citations (0)
Blastoid Mantle Cell Lymphoma of the Palate: Report of a Rare Aggressive Entity and Review of the Literature

2021 Head and Neck Pathology
Show All
- Source
- Cite
- Save
Citations (0)
Complete eradication of chronic lymphocytic leukemia with unusual skin involvement of high mitotic index after 12 cycles of Venetoclax/obinutuzumab

2021
Show All
- Source
- Cite
- Save
Citations (0)
Richter’s Transformation as leptomeningeal infiltration in a Chronic Lymphocytic Leukemia patient receiving Venetoclax. Could blood-brain barrier be a disease “sanctuary” during Venetoclax treatment?

2021
Show All
- Source
- Cite
- Save
Citations (0)
Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies.

2021 Annals of Hematology
Show All
- Source
- Cite
- Save
Citations (4)
Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study

2021 Cancers
Show All
- Source
- Cite
- Save
Citations (3)
Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy

2021 Blood Cancer Journal
Show All
- Source
- Cite
- Save
Citations (0)
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150).

2021 Blood Cancer Journal
Show All
- Source
- Cite
- Save
Citations (0)